Volkers A, Straatmijer T, Duijvestein M, Lowenberg M, et al. Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply. Aliment Pharmacol Ther 2023;57:743-744.
PMID: 36821751